Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05225805 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
A Phase 1 study, sponsored by Nabriva Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05225805 is a Phase 1 study that has completed, run by Nabriva Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT05225805, a Phase 1 study, has completed, sponsored by Nabriva Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is intended to assess the pharmacokinetic (PK) and safety of a single dose of IV and oral formulations of lefamulin in adults with cystic fibrosis (CF).
Interventions
- DRUG Lefamulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2023-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05225805
The ClinicalTrials.gov registry entry for NCT05225805 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabriva Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lefamulin is the first listed.
NCT05225805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05225805 about?
NCT05225805 is a clinical study titled "Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis". This study is intended to assess the pharmacokinetic (PK) and safety of a single dose of IV and oral formulations of lefamulin in adults with cystic fibrosis (CF).
What is the current status of trial NCT05225805?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2022-03-01. Estimated completion is 2023-01-13.
What interventions are being tested in trial NCT05225805?
The interventions under investigation include: Lefamulin (DRUG).
Who is sponsoring clinical trial NCT05225805?
This trial is sponsored by Nabriva Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.